Bijoy Hans Ltd

Bijoy Hans Ltd exhibits a strong liquidity position, with a current ratio of 18.42, indicating that the company holds significantly more current assets than current liabilities. The company's cash and equivalents amount to INR 16,254,350, which is a substantial portion of its total assets of INR 34,924,700. However, the company reported negative operating cash flow of INR -2,924,750, which may signal operational inefficiencies or high capital expenditures. In terms of profitability, the company is currently unprofitable, with a net income of INR -197,180 and an operating income of INR -903,220. The return on equity (ROE) is -0.0058, and the return on assets (ROA) is -0.0056, both of which are negative and significantly below the industry median for profitability metrics. This suggests that the company is not generating returns that meet the expectations of its shareholders or asset base. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. There is no indication of geographic diversification, and the company's revenue is entirely attributed to its primary business activity in Pharmaceuticals & Medical Research. This lack of diversification may expose the company to higher risk if market conditions in its primary segment deteriorate. Looking at the company's growth trajectory, there is no available data on revenue growth or future projections. The company's operating income and net income are both negative, which may indicate a need for strategic adjustments or cost management to improve profitability. The capital expenditure of INR -10,170 is relatively low, suggesting that the company is not heavily investing in new projects or infrastructure at this time. The risk assessment for Bijoy Hans Ltd indicates low liquidity and dilution risk. The company's debt-to-equity ratio is 0.02, which is very low, and there are no immediate filing-based liquidity or dilution flags. However, the negative operating cash flow and net income suggest that the company may need to consider alternative financing options in the future, which could potentially lead to dilution if equity is issued. There are no recent events or filings that have been disclosed in the available data. The company's financial performance and risk profile are based on the latest financial snapshot, and there is no indication of significant changes in the company's operations or strategic direction in the near term.